LANXESS India continues to support fight against COVID-19 through its CSR initiatives

• Donates 20 units of advanced German Ventilators to hospitals in Maharashtra, Madhya Pradesh and Gujarat• Supports District Hospital, Ujjain with 10 units of Oxygen Concentrators • Donates INR 10 lakhs to Employee State Insurance Corporation Hospital (ESIC) in Nagda as support for COVID-19 relief materials

Mumbai, May 18, 2021 – LANXESS India has committed over INR 2.1 crores as part of its CSR spends to support the medical infrastructure in the country in its fight against the Coronavirus pandemic. The spike in COVID-19 cases in the second wave has been severe and there has been a huge demand for critical medical equipment for treating patients. To help medical institutions tackle the situation better, LANXESS India has donated twenty units of advanced German Ventilators worth approximately INR 1.9 crores to hospitals in Thane & Mumbai (Maharashtra), Ujjain (Madhya Pradesh) and Ankleshwar & Bharuch (Gujarat).

The company donated these ventilators to nine hospitals in the states of Maharashtra, Madhya Pradesh and Gujarat where the company has its sites and offices. These include Kaushalya Medical Foundation Trust Hospital and Bethany Hospital in Thane, Shushrusha Hospital in Mumbai, Jayaben Modi Hospital in Ankleshwar, Sevashram Hospital and Civil Hospital in Bharuch, and Patidar Hospital, J K Hospital and SS Hospital & Research Centre in Ujjain. The hospitals will use these ventilators for treatment of COVID-19 patients.

In addition, to combat the rising medical oxygen requirement in the country, LANXESS India supported the District Hospital, Ujjain with ten units of Oxygen Concentrators. 

The company has also supported the Employee State Insurance Corporation Hospital (ESIC) in Nagda with INR 10 lakhs to help in upgrading their existing infrastructure and provide better medical assistance to the patients. 

Neelanjan Banerjee, Vice Chairman and Managing Director, LANXESS India commented, ”The current second wave of the Coronavirus pandemic in India has overwhelmed the medical infrastructure of our country and has led to a severe shortage of critical medical equipment. As part of our Corporate Social Responsibility efforts, we at LANXESS have yet again tried to support augmenting the infrastructure of some of the hospitals around our headquarters in Thane and our manufacturing sites in Nagda and Jhagadia. We will continue to aid the community in fighting the devastating second wave of COVID-19.”

In 2020-21, LANXESS India had contributed over INR 3.6 crores as part of its CSR spends for COVID-19 relief. It included contribution of INR 2 crores to the PM CARES Fund, 6 units of advanced German Ventilators to hospitals in Thane, donation of 1 tonne of its surface disinfectant, Rely+On™ Virkon™ and face masks among other relief materials.

LANXESS is a leading specialty chemicals company with sales of EUR 6.1 billion in 2020. The company currently has about 14,200 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Mumbai, May 18, 2021

Forward-Looking Statements

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Information for editors:

All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com

You can find further information concerning LANXESS chemistry in our WebMagazine at http://webmagazine.lanxess.com.

• Donates 20 units of advanced German Ventilators to hospitals in Maharashtra, Madhya Pradesh and Gujarat• Supports District Hospital, Ujjain with 10 units of Oxygen Concentrators • Donates INR 10 lakhs to Employee State Insurance Corporation Hospital (ESIC) in Nagda as support for COVID-19 relief materials

Mumbai, May 18, 2021 – LANXESS India has committed over INR 2.1 crores as part of its CSR spends to support the medical infrastructure in the country in its fight against the Coronavirus pandemic. The spike in COVID-19 cases in the second wave has been severe and there has been a huge demand for critical medical equipment for treating patients. To help medical institutions tackle the situation better, LANXESS India has donated twenty units of advanced German Ventilators worth approximately INR 1.9 crores to hospitals in Thane & Mumbai (Maharashtra), Ujjain (Madhya Pradesh) and Ankleshwar & Bharuch (Gujarat).

The company donated these ventilators to nine hospitals in the states of Maharashtra, Madhya Pradesh and Gujarat where the company has its sites and offices. These include Kaushalya Medical Foundation Trust Hospital and Bethany Hospital in Thane, Shushrusha Hospital in Mumbai, Jayaben Modi Hospital in Ankleshwar, Sevashram Hospital and Civil Hospital in Bharuch, and Patidar Hospital, J K Hospital and SS Hospital & Research Centre in Ujjain. The hospitals will use these ventilators for treatment of COVID-19 patients.

In addition, to combat the rising medical oxygen requirement in the country, LANXESS India supported the District Hospital, Ujjain with ten units of Oxygen Concentrators. 

The company has also supported the Employee State Insurance Corporation Hospital (ESIC) in Nagda with INR 10 lakhs to help in upgrading their existing infrastructure and provide better medical assistance to the patients. 

Neelanjan Banerjee, Vice Chairman and Managing Director, LANXESS India commented, ”The current second wave of the Coronavirus pandemic in India has overwhelmed the medical infrastructure of our country and has led to a severe shortage of critical medical equipment. As part of our Corporate Social Responsibility efforts, we at LANXESS have yet again tried to support augmenting the infrastructure of some of the hospitals around our headquarters in Thane and our manufacturing sites in Nagda and Jhagadia. We will continue to aid the community in fighting the devastating second wave of COVID-19.”

In 2020-21, LANXESS India had contributed over INR 3.6 crores as part of its CSR spends for COVID-19 relief. It included contribution of INR 2 crores to the PM CARES Fund, 6 units of advanced German Ventilators to hospitals in Thane, donation of 1 tonne of its surface disinfectant, Rely+On™ Virkon™ and face masks among other relief materials.

LANXESS is a leading specialty chemicals company with sales of EUR 6.1 billion in 2020. The company currently has about 14,200 employees in 33 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

Mumbai, May 18, 2021

Forward-Looking Statements

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors, nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person’s officers, directors or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

Information for editors:

All LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com. Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com

You can find further information concerning LANXESS chemistry in our WebMagazine at http://webmagazine.lanxess.com.

Follow us on Twitter, Facebook, Linkedin and YouTube:

Leave a Comment

Your email address will not be published. Required fields are marked *